Details of the Drug Combinations

General Information of This Drug (ID: DMLUA9D)

Drug Name
Simeprevir   DMLUA9D
Synonyms TMC436
Indication
Disease Entry ICD 11 Status REF
Chronic HCV-1 infection 1E51.1 Approved [1]
Renal hypoplasia N.A. Approved [2]
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

9 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Boceprevir + Simeprevir DC334QN Boceprevir Chronic Hepatitis C Infection [3]
Dolutegravir + Simeprevir DC4YBP1 Dolutegravir HIV [4]
Samatasvir + Simeprevir DC22557 Samatasvir Chronic Hepatitis C Infection [5]
Simeprevir + Daclatasvir DC8N7ND Daclatasvir Hepatitis C Virus [6]
Simeprevir + Sofosbuvir DCEALG2 Sofosbuvir Hepatitis C, Chronic [7]
Simeprevir + Sofosbuvir DCF1ADA Sofosbuvir Hepatitis C, Chronic [8]
Simeprevir + Sofosbuvir DCH4YYZ Sofosbuvir Hepatitis C Virus [9]
Simeprevir + Daclatasvir DCZ8I4I Daclatasvir Renal Impairment [10]
Simeprevir + Sofosbuvir DC3E5HG Sofosbuvir Hepatitis C Virus Infection [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7367).
2 Simeprevir FDA Label
3 ClinicalTrials.gov (NCT02333292) Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
4 ClinicalTrials.gov (NCT02404805) Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
5 ClinicalTrials.gov (NCT01813513) Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)
6 ClinicalTrials.gov (NCT01628692) Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
7 ClinicalTrials.gov (NCT02421211) A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
8 ClinicalTrials.gov (NCT02262728) An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
9 ClinicalTrials.gov (NCT02349048) Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
10 ClinicalTrials.gov (NCT02397395) An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
11 ClinicalTrials.gov (NCT02114151) Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis